BIOC News Alert Biocept Inc (BIOC) 2.48 12/25/2014 04:17:21

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biocept Inc (BIOC) 2.48 $BIOC

Biocept's Patented Platform Identifies Clinically HER2-Negative Patients With HER2-Positive Circulating Tumor Cells
GlobeNewswire - Wed Dec 17, 8:35AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), today announced the presentation of a poster at the 2014 San Antonio Breast Cancer Symposium. The presentation highlights Biocept's ability to identify patients who have developed HER2-positive CTCs during disease progression after an initial HER2-negative diagnosis by solid biopsy. The discovery of these patients, who may potentially be candidates for anti-HER2 treatment is made possible by OncoCEE-BR(TM), a breast cancer diagnostic developed using Biocept's CTC capture and analysis technology. The study was conducted at the Dana-Farber/Harvard Cancer Center.
BIOC: 2.48 (-0.04)

Biocept Expands Worldwide Microchannel Patent Protection to South Korea
GlobeNewswire - Mon Dec 15, 8:05AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that it has been granted a patent in South Korea for its fluidic microfluidic channel. The patent, Detection or Isolation of Target Molecules Using a Microchannel Apparatus, is the subject of Korean Patent Application No. 10-2009-7003339.
BIOC: 2.48 (-0.04)

Biocept Appoints Experienced Physician as Medical Director
GlobeNewswire - Wed Dec 03, 8:24AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced that Veena Singh, MD, FCAP, FCAMG has joined the Company as Senior Vice President and Senior Medical Director.
BIOC: 2.48 (-0.04)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 11:45AM CST

FRO: 2.43 (-0.01), SCOK: 2.92 (-0.01), NES: 4.96 (-0.44), OIIM: 2.18 (+0.01), BDR: 2.36 (+0.06), FRED: 16.64 (+0.20), MDGN: 5.19 (-0.02), NKA: 3.64 (+0.03), BIOC: 2.48 (-0.04), RVLT: 1.28 (-0.02), DY: 33.68 (+0.41), NDRM: 5.90 (-0.19), CRNT: 0.98 (+0.02), QIHU: 61.47 (+2.58), NFEC: 1.69 (+0.15), RLI: 48.88 (-0.20), ACI: 1.78 (+0.01), APT: 2.55 (-0.03), LAKE: 8.94 (+0.07), CASY: 89.15 (+0.12)

Nasdaq stocks posting largest volume increases
AP - Thu Nov 13, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
RESN: 8.79 (+0.45), FCVA: 4.34 (+0.10), GLBZ: 12.30 (unch), VGGL: 2.89 (+0.04), RDI: 12.78 (-0.18), CRDC: 0.69 (unch), BIOC: 2.48 (-0.04), WFD: 7.29 (+0.04), PLMT: 18.77 (+2.03), JAXB: 12.26 (+0.96), SUSQ: 13.43 (+0.01), RDIB: 12.46 (-0.42)

Biocept reports Q3 loss
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:55PM CST

BIOC: 2.48 (-0.04)

Biocept Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 13, 3:09PM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced its financial results for the third quarter ended September 30, 2014.
BIOC: 2.48 (-0.04)

Biocept Launches Lung Cancer Offering
GlobeNewswire - Wed Nov 12, 7:54AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA and Circulating Tumor Cells (CTCs), today announced the launch of its lung cancer liquid biopsy testing that will be performed at the Company's CLIA-certified and CAP-accredited laboratory.
BIOC: 2.48 (-0.04)

Biocept reports November 13
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 10:13AM CST

BIOC: 2.48 (-0.04)

Biocept, Inc. Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 7:42AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), today announced that the Company will issue its financial results for the third quarter of 2014 on Thursday, November 13, 2014, after the close of the market, and will hold a conference call on this day at 4:30 p.m. ET to discuss the financial results and provide a company update.
BIOC: 2.48 (-0.04)

Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells
GlobeNewswire - Mon Oct 13, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), and Rosetta Genomics, Ltd. (Nasdaq:ROSG), a leading molecular diagnostics company advancing microRNA-based diagnostics based on its proprietary microRNA platform technologies, today announced a collaboration that will combine both companies' platform technologies in an innovative approach to cancer diagnostics. The collaboration will utilize Biocept's patented microfluidic channel technology to capture CTCs and then apply Rosetta Genomics' technical expertise and proprietary methods to extract and analyze microRNA from these cells. The companies will test for markers currently offered by Rosetta as well as pursue new potential markers.
ROSG: 2.35 (+0.03), BIOC: 2.48 (-0.04)

Market Maker Surveillance Report. ISSC, CBK, ANV, BIOC, OMAG, TCS, Losing Stocks With Lowest Price Friction For Tuesday, October 7th 2014
M2 - Wed Oct 08, 4:24AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4746 companies with "abnormal" market making, 1204 companies with positive Friction Factors and 3932 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Innovative Solutions and Support Inc (NASDAQ:ISSC), Christopher & Banks Corp (NYSE:CBK), Allied Nevada Gold Corp (NYSE:ANV), BioClinica Inc (NASDAQ:BIOC), Omagine Inc (OTC:OMAG), (NYSE:TCS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ANV: 0.88 (+0.02), CBK: 5.44 (-0.16), ISSC: 2.87 (-0.06), TCS: 20.22 (+0.20), BIOC: 2.48 (-0.04)

Biocept Expands Collaboration With MD Anderson Cancer Center
GlobeNewswire - Tue Oct 07, 7:39AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today announced the furthering of its collaboration with The University of Texas MD Anderson Cancer Center regarding studies focused on patients diagnosed with ovarian cancer.
BIOC: 2.48 (-0.04)

Biocept to Present at the 13th Annual BIO Investor Forum
GlobeNewswire - Tue Sep 30, 7:31AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to present a corporate overview at the 13 Annual BIO Investor Forum on October 7, 2014 at The Palace Hotel in San Francisco.
BIOC: 2.48 (-0.04)

Biocept Granted Patent in China for Its Microfluidic Channel Technology Used to Capture Circulating Tumor Cells
GlobeNewswire - Thu Sep 18, 9:34AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that the Company has been granted a patent in China for its microfluidic channel technology used to capture CTCs. The granted patent is the subject of Chinese Patent No. ZL200780032530.2, entitled, "Detection or Isolation of Target Molecules Using a Microchannel Apparatus."
BIOC: 2.48 (-0.04)

Biocept to Present at Upcoming Investor Conferences
GlobeNewswire - Thu Sep 04, 7:36AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that Michael Nall, Biocept President and CEO, will be presenting a corporate overview at the following upcoming investor conferences:
BIOC: 2.48 (-0.04)

Biocept Strengthens Its Circulating Tumor Cell IP Position in Europe
GlobeNewswire - Wed Sep 03, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that the opposition period has expired for challenging the validity of its European Patent No. 1838442, entitled, "Cell Separation Using Microchannel Having Patterned Posts." This patent supports the proprietary microfluidics blood-based technology Biocept uses to capture CTCs.
BIOC: 2.48 (-0.04)

Biocept Provides Second Quarter Operational Update
GlobeNewswire - Thu Aug 14, 7:31AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today provided a business update following the recent filing with the US Securities and Exchange Commission of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2014.
BIOC: 2.48 (-0.04)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 45

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 71

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 159

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 45

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights into Carvana's Growing Options Market Activity

Updated Category News Views 105

Carvana's Options Market Activity Investors with substantial capital are displaying a bullish sentiment towards Carvana Co (NYSE: CVNA). This developing trend in the options market is noteworthy and shouldn't be overlooked by market participants. Recent analyses have revealed an intriguing series of activities that hint at significant upcoming developments for Carvana....

Continue Reading
Road Warrior Expands Network with Big Acquisitions

Updated Category News Views 30

A Heavy-Duty Play: Road Warrior's Big Moves You might think in the world of heavy-duty parts and service, things move like a freight train—slow and steady. But here comes Road Warrior Parts & Service, full steam ahead with a string of acquisitions that are shaking up the landscape. If you've been snoozing on this sector, it's time to wake up. The Acquisitions That Are...

Continue Reading
Foresight Group Commences Strategic Share Buyback Programme

Updated Category News Views 358

Foresight Group Commences Strategic Share Buyback Programme Foresight Group Holdings Limited (LSE: FSG), a well-respected leader in investment management for real assets, is pleased to announce a new initiative as part of its ongoing commitment to creating shareholder value. This new share buyback programme, announced recently, underscores its proactive approach to...

Continue Reading
Carvana's New Delivery Service Lifts Stock Prices Significantly

Updated Category News Views 164

Overview of Carvana's Recent Stock Movement Carvana Co (NYSE: CVNA) has seen its stock rise as it introduces new service options. Recently, the company extended its same-day vehicle delivery feature to customers in the San Diego area, marking a significant enhancement in its operations. By allowing locals to receive their purchased vehicles on the same day they place an...

Continue Reading
AI-Powered Travel Transformation in Norway Revealed

Updated Category News Views 130

AI-Driven Travel Meets Norway's Authentic Charm Well, folks, once again we're staring down the barrel of technology going full throttle in the travel game. Mindtrip, the savvy AI-powered travel platform, just inked a deal with the Norwegian Travel Cluster. It's their first tango in Europe, and they're not dipping their toes—they're diving headfirst into the icy fjords....

Continue Reading